Natrecor for Pulmonary Hypertension in Lung Transplants

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study seeks to demonstrate that Natrecor® (nesiritide) is safe and effective and has a favorable hemodynamic profile in lung transplant recipients that will allow for the avoidance of inhaled nitric oxide (iNO) use. It is estimated that the use of nesiritide will decrease the otherwise historically mandated use of iNO by 50%, as compared to the necessity of iNO use by matched historical controls.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Treatments: Natriuretic Peptide, Brain

Criteria

Inclusion Criteria:

• Single or double lung transplant or heart/lung transplant recipient

• Planned use of Natrecor

• Pulmonary artery (PA) systolic pressures > 35

Exclusion Criteria:

• Previous lung transplant

• Use of Prolastin after pneumonectomy

• Mean arterial pressure of < 55

• Known allergy or sensitivity to nesiritide

• Females of childbearing potential with a positive pregnancy test or women who are breast feeding

• Use of nesiritide, for any reason, within 30 days prior to transplant